Gigapixel digital PCR in Giant Unilamellar Vesicles

巨型单层囊泡中的十亿像素数字 PCR

基本信息

  • 批准号:
    10425412
  • 负责人:
  • 金额:
    $ 61.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-30 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Infectious disease remains a major cause of morbidity across the globe. Successful medical intervention requires accurate diagnosis, which can be challenging due to symptoms shared among infections. Moreover, increasing drug resistance makes it important to identify and characterize pathogenic microbes and choose effective treatments in a timely manner. In this competing renewal, we will extend technology developed under our previous R01 to enable rapid, sensitive, and information-rich infectious disease diagnosis. Our new technology, which we dub Gigapixel NGS, extends our Gigapixel digital PCR (dPCR) technology from the previous R01 by incorporating a powerful next-generation sequencing capability. The core innovation of Gigapixel dPCR was to perform dPCR assays in double emulsion vesicles, rather than conventional water-in- oil droplets utilized by commercial dPCR instruments (Bio-Rad, RainDance). Vesicles obviate the need for specialized droplet analyzers and allow common flow cytometers to be used for quantification. Flow cytometers are ubiquitous in research and clinical labs, with superior analysis capabilities (i.e. speed, sensitivity, and multiplexing) in comparison to specialized droplet analyzers. This allows Gigapixel dPCR to increase the number of compartments that can be analyzed to over 100 million, providing a 100-fold increase in sensitivity of quantification. Moreover, flow cytometers can sort out vesicles in which PCR has detected a DNA target, a functionality not found in existing droplet analyzers. In this competing renewal, we will leverage the capability of Gigapixel NGS to detect, isolate and sequence infectious pathogen genomes directly from patient samples. The proposed workflow will increase the efficiency and sensitivity of pathogen sequencing, yielding higher-quality draft genomes at far lower cost. In collaboration with Dr. Charles Chiu, an infectious disease physician at UCSF specializing in clinical sample sequencing for pathogen detection, we will develop bioinformatic tools to interrogate the recovered genomes for relevant biomarker sequences, such as virulence factors and drug resistance genes. Through further collaboration with Fluent Biosciences, we will adapt Gigapixel NGS to their commercial platform, allowing the protocol to be implemented by research and clinical labs as a commercially available kit. The Specific Aims of our proposal are to: 1) Extend Gigapixel PCR into a clinically relevant platform, in the form of Gigapixel NGS. 2) Demonstrate integrated quantification and accurate genome sequencing of bacterial infections in meningitis. 3) Apply the technology for in silico identification and diagnosis of flavivirus infections from (liquid) biopsy samples such as plasma and cerebrospinal fluid.
摘要 传染病仍然是全球发病率的主要原因。成功的医疗干预 需要准确的诊断,这可能是具有挑战性的,因为感染之间有共同的症状。此外, 耐药性的增加使得识别和表征致病微生物并选择 及时有效的治疗。在这一竞争更新中,我们将扩展在 我们之前的R01能够实现快速、灵敏和信息丰富的传染病诊断。我们的新产品 我们称之为Gigapixel NGS的技术将我们的Gigapixel Digital PCR(DPCR)技术从 之前的R01通过整合强大的下一代测序功能而实现。的核心创新之处 Giapixel dPCR是在双乳泡中进行dPCR分析,而不是传统的水在... 商用dPCR仪器(Bio-Rad、RainDance)使用的油滴。小泡不再需要 专门的液滴分析仪,并允许使用普通的流式细胞仪进行定量。流式细胞仪 在研究和临床实验室中无处不在,具有卓越的分析能力(即速度、灵敏度和 多路传输)与专门的液滴分析仪进行比较。这使得Gigapixel dPCR可以增加 可分析的隔室数量超过1亿个,灵敏度提高100倍 量化的结果。此外,流式细胞仪可以分选出聚合酶链式反应检测到DNA靶标的囊泡。 现有液滴分析仪没有的功能。 在这一竞争更新中,我们将利用Gigapixel NGS的能力来检测、分离和排序 直接从患者样本中提取感染性病原体基因组。建议的工作流程将提高效率 以及病原体测序的敏感性,以低得多的成本产生更高质量的草稿基因组。在协作中 与加州大学旧金山分校的传染病内科医生Charles Chiu博士合作,专门从事临床样本测序 病原体检测,我们将开发生物信息学工具来询问恢复的基因组,以便相关 生物标记物序列,如毒力因子和耐药基因。通过进一步与 流畅的生物科学,我们将使Gigapixel NGS适应他们的商业平台,允许协议 由研究和临床实验室作为商业可用试剂盒实施。 我们建议的具体目标是: 1)将Gigapixel PCR扩展到临床相关平台,以Gigapixel NGS的形式出现。 2)展示细菌感染的综合量化和准确的基因组测序 脑膜炎。 3)将该技术应用于黄病毒感染的电子鉴定和诊断。 血浆和脑脊液等样本。

项目成果

期刊论文数量(40)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Peering below the diffraction limit: robust and specific sorting of viruses with flow cytometry.
  • DOI:
    10.1186/s12985-016-0655-7
  • 发表时间:
    2016-12-01
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Lance ST;Sukovich DJ;Stedman KM;Abate AR
  • 通讯作者:
    Abate AR
Combined aptamer and transcriptome sequencing of single cells.
  • DOI:
    10.1038/s41598-018-21153-y
  • 发表时间:
    2018-02-13
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Delley CL;Liu L;Sarhan MF;Abate AR
  • 通讯作者:
    Abate AR
Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia.
  • DOI:
    10.1038/s41467-021-21810-3
  • 发表时间:
    2021-03-11
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Demaree B;Delley CL;Vasudevan HN;Peretz CAC;Ruff D;Smith CC;Abate AR
  • 通讯作者:
    Abate AR
Precision ejection of microfluidic droplets into air with a superhydrophobic outlet.
  • DOI:
    10.1039/d0lc01327g
  • 发表时间:
    2021-04-20
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Zhang P;Chang KC;Abate AR
  • 通讯作者:
    Abate AR
Robotic automation of droplet microfluidics.
  • DOI:
    10.1063/5.0064265
  • 发表时间:
    2022-01
  • 期刊:
  • 影响因子:
    3.2
  • 作者:
    Tran TM;Kim SC;Modavi C;Abate AR
  • 通讯作者:
    Abate AR
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Adam R. Abate其他文献

FIND-seq: high-throughput nucleic acid cytometry for rare single-cell transcriptomics
FIND-seq:用于罕见单细胞转录组学的高通量核酸细胞计数术
  • DOI:
    10.1038/s41596-024-01021-y
  • 发表时间:
    2024-07-22
  • 期刊:
  • 影响因子:
    16.000
  • 作者:
    Seung Won Shin;Prakriti Mudvari;Shravan Thaploo;Michael A. Wheeler;Daniel C. Douek;Francisco J. Quintana;Eli A. Boritz;Adam R. Abate;Iain C. Clark
  • 通讯作者:
    Iain C. Clark

Adam R. Abate的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Adam R. Abate', 18)}}的其他基金

Next Generation Infectious Disease Diagnostics: Microfluidic-Free Gigapixel PCR with Self-Assembled Partitioning
下一代传染病诊断:具有自组装分区的无微流控千兆像素 PCR
  • 批准号:
    10682295
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
Sorting and Sequencing Latent Reservoirs in HIV+ Opioid Users
HIV阿片类药物使用者中潜在储库的分类和测序
  • 批准号:
    10789790
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
A non-invasive metabolic sensor for improving success in IVF
用于提高 IVF 成功率的非侵入性代谢传感器
  • 批准号:
    10741730
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
Identification of regulatory mechanisms operating in rare pathogenic astrocyte subsets in multiple sclerosis with a novel genomic technology
利用新型基因组技术鉴定多发性硬化症中罕见致病性星形胶质细胞亚群的调节机制
  • 批准号:
    10737509
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution
用于超高通量生物催化剂进化的通用液滴微流控平台
  • 批准号:
    10547670
  • 财政年份:
    2021
  • 资助金额:
    $ 61.92万
  • 项目类别:
A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution
用于超高通量生物催化剂进化的通用液滴微流控平台
  • 批准号:
    10705725
  • 财政年份:
    2021
  • 资助金额:
    $ 61.92万
  • 项目类别:
Ultrahigh Throughput Microscale Mass Spectrometry for Pharmaceutical Prenylation Enzyme Engineering
用于药物异戊二烯化酶工程的超高通量微型质谱分析
  • 批准号:
    10325565
  • 财政年份:
    2021
  • 资助金额:
    $ 61.92万
  • 项目类别:
Multi-omic dissection of the transcriptional, epigenetic, and proteomic signatures of cells infected with latent HIV
对潜伏 HIV 感染细胞的转录、表观遗传和蛋白质组学特征进行多组学分析
  • 批准号:
    10447107
  • 财政年份:
    2020
  • 资助金额:
    $ 61.92万
  • 项目类别:
A platform for engineering peptide ligase for building next generation peptide therapeutics.
用于构建下一代肽疗法的肽连接酶工程平台。
  • 批准号:
    9908228
  • 财政年份:
    2020
  • 资助金额:
    $ 61.92万
  • 项目类别:
Multi-omic dissection of the transcriptional, epigenetic, and proteomic signatures of cells infected with latent HIV
对潜伏 HIV 感染细胞的转录、表观遗传和蛋白质组学特征进行多组学分析
  • 批准号:
    10197751
  • 财政年份:
    2020
  • 资助金额:
    $ 61.92万
  • 项目类别:

相似海外基金

New roles of IFN-inducible OAS proteins in innate immune defense against bacterial infections
IFN诱导的OAS蛋白在针对细菌感染的先天免疫防御中的新作用
  • 批准号:
    10649771
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
Derivation and validation of a clinical prediction rule to identify febrile infants 61 to 90 days old at low and non-negligible risk of invasive bacterial infections
推导和验证临床预测规则,以识别 61 至 90 天大的发热婴儿,其侵袭性细菌感染的风险较低且不可忽略
  • 批准号:
    10574286
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
Structural and functional studies of YbtPQ for fighting bacterial infections
YbtPQ 对抗细菌感染的结构和功能研究
  • 批准号:
    10644889
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
A gut feeling: How can gastrointestinal bacterial infections alter female reproductive tract immunity and control of sexually transmitted infections
直觉:胃肠道细菌感染如何改变女性生殖道免疫力和性传播感染的控制
  • 批准号:
    MR/X031993/1
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
    Research Grant
Molecular probes to diagnose pathoadapatations in bacterial infections
诊断细菌感染病理适应的分子探针
  • 批准号:
    EP/X014479/1
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
    Research Grant
Using Small Area Variation Analysis to Investigate Sources of Practice Variation for Febrile Infants at Risk for Invasive Bacterial Infections
使用小面积变异分析来调查有侵袭性细菌感染风险的发热婴儿的实践变异来源
  • 批准号:
    10588846
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
宿主定向 Orynotide 用于治疗耐多药革兰氏阴性细菌感染
  • 批准号:
    10674221
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
SimCell vaccines against Staphylococcus aureus bacterial infections
针对金黄色葡萄球菌细菌感染的 SimCell 疫苗
  • 批准号:
    10073241
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
    Grant for R&D
I-Corps: Mitigating Multidrug Resistant Bacterial Infections with Biocompatible and Environmentally Benign Nanoantibiotics
I-Corps:利用生物相容性且对环境无害的纳米抗生素减轻多重耐药细菌感染
  • 批准号:
    2306943
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
    Standard Grant
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 61.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了